VC
AIMT

Vivo Capital’s Aimmune Therapeutics AIMT Stock Holding History

Vivo Capital’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-306,872
Closed -$9.77M – 41
2018
Q1 		$9.77M Sell
306,872
-336,754
-52% -$11.9M 1.38% 18
2017
Q4 		$24.3M Sell
643,626
-133,187
-17% -$4.3M 5.21% 8
2017
Q3 		$19.3M Hold
776,813
– – 3.89% 11
2017
Q2 		$16M Buy
776,813
+13,804
+2% +$263K 4.02% 8
2017
Q1 		$16.6M Hold
763,009
– – 4.88% 7
2016
Q4 		$15.6M Hold
763,009
– – 5.14% 6
2016
Q3 		$11.4M Hold
763,009
– – 3.57% 10
2016
Q2 		$8.26M Buy
+763,009
New +$10.4M 2.25% 11

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vivo Capital's AIMT Position: Q2 2018 in Review

Vivo Capital sold out of Aimmune Therapeutics (AIMT) in Q2 2018, closing a stake of 306,872 shares — an estimated $9.77M sold.

Vivo Capital first reported a position in AIMT in Q2 2016 and held it in 8 quarters. The position peaked at $24.3M in Q4 2017. 151 funds tracked by Wall St. Rank hold AIMT as of Q2 2018.

  • Vivo Capital reported no remaining Aimmune Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Vivo Capital sold 306,872 Aimmune Therapeutics shares in Q2 2018, an estimated $9.77M.
  • Vivo Capital first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 8 quarters.
  • Vivo Capital's Aimmune Therapeutics position peaked at $24.3M in Q4 2017.
  • 151 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2018.

Based on Vivo Capital's 13F filing for Q2 2018, filed 10 Aug 2018.